Further Efforts To Protect Access to Reproductive Healthcare Services

What Presidential Memorandum 2023-01691 says

Federal Register, Volume 88 Issue 17 (Thursday, January 26, 2023) [Federal Register Volume 88, Number 17 (Thursday, January 26, 2023)] [Presidential Documents] [Pages 4895-4897] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2023-01691] Presidential Documents Federal Register / Vol. 88, No. 17 / Thursday, January 26, 2023 / Presidential Documents [[Page 4895]] Memorandum of January 22, 2023 Further Efforts To Protect Access to Reproductive Healthcare Services Memorandum for the Attorney General[,] the Secretary of Health and Human Services[, and] the Secretary of Homeland Security By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered as follows: Section 1. Policy. Since 2000, the medication mifepristone has been approved by the Food and Drug Administration (FDA) for use in the United States as a safe and effective method to end early pregnancy. The Food and Drug Administration Amendments Act of 2007 (Public Law 110-85) requires the FDA, working with drug manufacturers, to specify conditions for the use of certain drugs after considering six congressionally mandated factors. The Act sets forth a detailed administrative process to develop such conditions for use, known collectively as the Risk Evaluation and Mitigation Strategies (REMS), for individual...

Opening of the official text; read it in full in the Federal Register.